The Jain Foundation’s mission is to cure muscular dystrophies caused by dysferlin protein deficiency. These dystrophies are collectively termed dysferlinopathy, but are also referred to as LGMD2B, LGMDR2, or Miyoshi Myopathy 1 (MM1). Dysferlinopathy is an orphan disease afflicting approximately 8-10 people/million and receives little or no funding from traditional sources. The Foundation’s focused strategy includes funding and actively monitoring the progress of scientific research projects in key pathways towards a cure, providing financial and logistical support to promising drug candidates to accelerate them to clinical trials, funding clinical trials and studies, encouraging collaboration among scientists, and educating dysferlinopathy patients about their disease and helping them with their diagnosis.